Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Gains As Market Dips: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $77.47, marking a +0.43% move from the previous day.

Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.

AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting

AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.

Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN

Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Congressional Activities on Shutdown in Focus

Congressional Activities on Shutdown in Focus

AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down

AbbVie (ABBV) misses estimates for both earnings and revenues in fourth quarter. Biosimilar competition impacts Humira sales in ex-U.S. markets. Imbruvica and Mavyret offset Humira decline.

Mark Vickery headshot

Asia, Congress Activity, Put Futures in the Green

Market indexes are up in today's pre-market ??? the Dow in the green a healthy triple digits ??? despite a disappointing earnings call from Intel and comments from the Commerce Secretary yesterday.

Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV

J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.

AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down

AbbVie's (ABBV) fourth-quarter 2018 earnings and revenues both missed estimates. The company provided 2019 guidance International Humira sales suffered due to biosimilar competition.

AbbVie (ABBV) Lags Q4 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of -1.04% and -0.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?

While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings?

Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q4 sales, genericization of key drugs and weak sales in the EH segment will hurt the same.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q4 Earnings

With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.

The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb

The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb

Zacks Investment Ideas feature highlights: International Business Machines, Procter and Gamble, Ford, Intel and Abbvie

Zacks Investment Ideas feature highlights: International Business Machines, Procter and Gamble, Ford, Intel and Abbvie

Is a Surprise Coming for AbbVie (ABBV) This Earnings Season?

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.

David Borun headshot

Blue Chips IBM and Proctor and Gamble Rally on Earnings

Investors are delighted with improved guidance as well as solid earnings

Mark Vickery headshot

Top Research Reports for Amazon, Verizon & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Verizon (VZ) and AbbVie (ABBV).

Tracey Ryniec headshot

5 Amazing Earnings Charts

It's not easy to beat nearly every quarter for years but these 5 companies have been doing just that.

J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft

J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.